No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
CN Stock MarketDetailed Quotes
300573 Shenyang Xingqi Pharmaceutical
- 141.33
- +0.33+0.23%
Market to Open Jul 23 09:30 CST
24.65BMarket Cap96.54P/E (TTM)
141.33High141.33Low43lotVolume141.33Open141.00Pre Close607.72KTurnover0.00%Turnover Ratio102.71P/E (Static)174.42MShares214.3652wk High18.09P/B18.94BFloat Cap77.5252wk Low169.20Limit Up133.99MShs Float214.36Historical High112.80Limit Down0.00%Amplitude-1.10Historical Low2.65Dividend TTM141.33Avg Price43.00lotAsk1.88%Div YieldTTM100Lot Size0lotBid
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
No Data
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Zhu Shaoxing disclosed the Q2 report of his fund, with a significant shareholding reduction in Kweichow Moutai (600519.SH).
Recently, Zhu Shaoxing, the star fund manager of Fund Manager, revealed the second quarter report of his fund holdings in 2024. Currently, Zhu Shaoxing only manages one fund, the Fuguo Tianhuicheng Growth Hybrid Fund, with a management scale of nearly RMB 27 billion as of the end of the second quarter.
The latest development of Zhu Shaoxing's shareholding has been exposed! He reduced his shareholding in Maotai for two consecutive quarters and increased his holdings in these companies continuously.
Continuously increasing or decreasing shareholdings of these stocks for five consecutive quarters.
Here's Why We Think Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Is Well Worth Watching
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. But as
Individual Investors Are Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) Biggest Owners and Were Hit After Market Cap Dropped CN¥3.3b
Key Insights Significant control over Shenyang Xingqi PharmaceuticalLtd by individual investors implies that the general public has more power to influence management and governance-related decisions
Does Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when
Sinqi Pharmaceutical (300573.SZ): There is currently no medicine to treat flying mosquito disease
Gelonghui, May 28 | An investor asked Sinqi Pharmaceutical (300573.SZ) on the investor interactive platform, “Please ask if your company has any drugs or R&D projects to treat “flying mosquito disease.” The company replied that the company currently has no drugs to treat flying mosquito disease.
Comments
The company's high P/S ratio is backed by strong forecasted revenue growth, outpacing the rest of the Pharmaceuticals industry. Investors anticipate this growth, justifying a higher stock price. A significant share price drop is unlikely under these conditions.
Market Participants Recognise Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) Revenues Pushing Shares 26% Higher 2
Shenyang Xingqi Pharmaceutical's strong financials and high ROE hint at potential long-term stock value increase. Impressive net income growth and efficient earnings reinvestment suggest a positive outlook.
Despite Shenyang Xingqi Pharmaceutical Ltd's weak recent revenue performance, the high P/S ratio points to investors holding stocks, anticipating significant revenue recovery. But with forecasted growth mirrored by the industry, the current ratio may not be sustainable without improved performance.
Despite Shenyang Xingqi's lackluster revenue growth, the high P/S ratio implies investors are holding stocks in anticipation of a major revenue rebound. Yet, the expected revenue growth that matches with the industry's might not uphold this high P/S in the long run. An uplift in performance is necessary to justify this current ratio.
Shenyang Xingqi PharmaceuticalLtd's performance appears to be quite favorable, particularly due to high reinvestment of its profits leading to substantial earnings growth. Analysts are expecting the company to continue its recent growth streak.
Read more
Analysis
Price Target
No Data
Heat List
CN
Overall
Symbol
Latest Price
%Chg